type-i

Anti-Human/Mouse denatured collagen type-I Antibody (XL313) is an IgG1, κ inhibitor derived from mice, targeting denatured collagen type-I in both human and mouse.

Obinutuzumab (Obinutuzumab/afutuzumab) GA101) is a glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.

Gevokizumab (S-78989) is a humanised monoclonal antibody targeting IL-1β, which blocks IL-1β signalling through allosteric regulation, and can be used for diabetes, cancer, inflammation, and cardiovascular diseases.

Bifarcept, a recombinant antibody targeting the interferon receptor type I (IFN-RI), enhances the serum half-life of IFN-β by facilitating its binding.

Zelminemab (AMG-301) is a humanized monoclonal antibody targeting the pituitary adenylate cyclase-activating polypeptide type I receptor (ADCYAP1R1) for use in neurological disorders.

Valanafusp alfa (AGT-181) is a recombinant fusion protein combining a chimeric monoclonal antibody targeting the human insulin receptor (HIR) with human iduronidase (IDUA), facilitating brain penetration, and is utilized in researching Mucopolysaccharidosis type I (MPS I) [1].

Interferon alfa, a type I interferon, activates new genes, displaying strong antiviral and antiproliferative effects on target cells. It signals through receptor-mediated activation of Stat1 and Stat2, which heterodimerize into a STAT complex binding with the DNA-binding protein IRF-9 (p48) to form ISGF-3 (IFN-stimulated gene factor 3). This complex further activates driver genes to fulfill its antiviral role [1].

Anifrolumab(MEDI-546) is a potent type I interferon (IFN) receptor antagonist, a human monoclonal antibody that targets IFN.Anifrolumab inhibits the activity of type I interferon and is used for the prevention and treatment of systemic lupus erythematosus (SLE).

Atibuclimab is a chimeric monoclonal antibody targeting CD14, consisting of a mouse variable region and a human IgG4 Fc region. Atibuclimab can be used to treat amyotrophic lateral sclerosis. Atibuclimab reduces LPS-induced disease and inhibits LPS-induced pro-inflammatory cytokine release, delaying the release of anti-inflammatory cytokine soluble TNF receptor type I.

Lepunafusp alfa (JR-171) is a blood-brain barrier-penetrating fusion protein comprising J-Brain Cargo and α-L-iduronidase (IDUA), a lysosomal enzyme. This compound effectively lowers levels of heparan sulfate (HS) and dermatan sulfate (DS) and is utilized in the study of mucopolysaccharidosis type I [1] [2].

Ertumaxomab (Anti-Human CD22 Recombinant Antibody) is a bispecific antibody that targets both HER2/neu and CD3. It functions by activating Fcγ type I/III receptors, which facilitates the formation of a tri-cell complex involving tumor cells, T cells, and accessory cells. This compound has been utilized in the research of breast cancer [1].

ALD1910 is a humanized monoclonal antibody targeting PACAP38 and PACAP27. It inhibits PACAP signaling through pituitary adenylate cyclase-activating peptide type I receptor (PAC1-R), vasoactive intestinal peptide receptor 1 (VPAC1-R), and VPAC2-R. ALD1910 recognizes a non-linear epitope within PACAP and prevents its binding to cell surfaces. It is useful for studying PACAP-mediated migraines.

Anti-Mouse CD40 Antibody (FGK4.5/FGK45) is a rat-derived IgG2a monoclonal antibody targeting mouse CD40, a type I transmembrane glycoprotein within the tumor necrosis factor receptor (TNFR) superfamily. CD40 functions as a costimulatory molecule, activating B cells, dendritic cells, monocytes, and other antigen-presenting cells (APC), thereby enhancing antitumor T cell responses.